UTv Videos

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.

Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.

Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.

Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Mark D. Tyson II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.

Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.

Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.

Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.

Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.

Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.

Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.